[The current status of postoperative adjuvant chemotherapy for colorectal cancer].
To evaluate the significance of postoperative adjuvant chemotherapy, randomized controlled trials of adjuvant chemotherapy after curative resection for colorectal cancer were reviewed. Several multiple-drug systemic chemotherapy (MOF, MMC/FT p.o., MMC/5-FU p.o., MMC/ UFT po) were useful as adjuvant treatment to improve survival or disease-free survival for patients with colorectal cancer. And worldwide meta-analysis found that continuous intraportal 5-FU was suggested to improve survival. Recently, combination chemotherapy trials utilizing 5-FU and levamisole, or 5-FU and leucovorin, demonstrated significant a survival advantage in the patients with high risk colon cancer, and these are widely used as adjuvant treatment for patients with Dukes C resected colon cancer. From results of many Japanese trials, although the effectiveness of adjuvant treatment for colorectal cancer still remain controversial, postoperative adjuvant chemotherapy is thought to improve the disease-free survival of patients after resection of rectal cancer or Dukes C colon cancer.
Kodaira
S
S
First Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012673:Semustine / Q000008:administration & dosage; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D012673:Semustine; D016685:Mitomycin; D014750:Vincristine; D005472:Fluorouracil